40 Objective Comparison of Postoperative Activity After Sentinel Lymph Node Biopsy vs Axillary Node Clearance Using Wearable Activity Monitors

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 34-35

Nur Amalina Che Bakri, BMedSc1; Richard M. Kwasnicki, PhD, MRCS1; K Dhillon, O Ghandour, N Khan, A Cairns, H Ashrafian, A Darzi, D Leff

1Imperial College of London, London, UK.

Background

Anecdotal evidence shows that patients who have axillary node clearance (ANC) are more likely to experience shoulder morbidities such as reduced range of motion, pain, and lymphedema compared with those who undergo sentinel lymph node biopsy (SLNB). However, the evidence is largely subjective and based on patient surveys. Wearable activity monitors (WAMs) are increasingly used in oncology trials to monitor patients’ daily activities. We aimed to use WAMs in order to capture a more reliable and objective measure of physical function; this could help define the recovery process across different treatments, specifically looking at the impact of ANC vs SLNB on patient recovery.

Materials and Methods

A single-center, prospective, observational study was conducted involving 41 patients. Consecutive patients undergoing breast and axillary surgery were identified from theater lists. Patients with movement disorders (eg, Parkinson disease), those using mobility devices or aids, and those who were unable to provide informed consent were excluded from the study. Eligible consented patients wore WAMs (triaxial accelerometer [AX3]; Axivity, UK) on both wrists at least 1 day pre- and up to 2 weeks postoperatively, and completed Disability of the Arm, Shoulder and Hand (DASH) and quality-of-life (EQ-5D) questionnaires. Analysis was focused on patients who had SLNB and ANC. Statistical analysis was performed to determine the recovery plateau and differences in activity between arms (operated vs control) and surgeries.

Results

Regain of function was seen through the increase of activity during the postoperative period, with the greatest increase between day 1 (mean, 41.5+/–19.6; P <.05) and 2 (mean, 51.5+/–22.1; P <.05), with recovery plateau at day 5. Greater activity was observed in the control arm compared with the operated arm, with a significant difference (P <.05) in week 1. Greater reduction of activity from preoperative level was observed in ANC patients compared with SLNB cohort throughout the 2-week period, with significant differences of 14.5% (P <.05) in week 1 and 18.8% in week 2 (P <.005). Moderate negative correlation was found between the postoperative activity levels and postoperative DASH questionnaires (Spearman = –0.512; P <.05).

Conclusions

ANC patients took longer to reach preoperative activity levels compared with SLNB patients, in concordance with anecdotal evidence in the literature. Monitoring recovery objectively after breast cancer treatment may help patients and clinicians to choose the best option, particularly where oncological outcomes are equivocal. This information can also be used to ensure optimization of patient outcomes by encouraging physical activity and keeping track of personalized activity goals, which could be integrated into the feedback-enabled and personalized prehabilitation and rehabilitation care plan.

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients
Related Content